// App-Quantinova.ai

POS1029 (2021) : GUSELKUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENTS IN GENERAL HEALTH OUTCOMES MEASURED WITH PROMIS-29 THROUGH 52 WEEKS: RESULTS FROM THE PHASE 3 DISCOVER-1 TRIAL

Researchers

Presenter

  • A. M. Orbai

Principal Investigators

  • L. C. Coates

  • A. Deodhar

  • P. Helliwell

  • C. T. Ritchlin

  • A. Kollmeier

  • E. C. Hsia

  • X. L. Xu

  • S. Sheng

  • Y. Jiang

  • Y. Liu

  • C. Han

Medical Centers

  • Johns Hopkins University School of Medicine, Psoriatic Arthritis Program, Baltimore, United States of America

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • Oregon Health and Science University, Rheumatology Clinica Division of Arthritis and Rheumatic Diseases, Portland, United States of America

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • University of Rochester, Allergy/Immunology and Rheumatology, Rochester, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • University of Pennsylvania, Perelman School of Medicine, Department of Dermatology, Philadelphia, United States of America

  • Janssen Research & Development, Raritan, United States of America

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Depression

  • Inflammatory Arthritis

  • Anxiety

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved